Published in PLoS One on June 29, 2012
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
Vaccine development for tuberculosis: current progress. Drugs (2013) 1.01
Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med (2014) 1.00
Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol (2013) 0.95
The next 10 years for tuberculosis vaccines: do we have the right plans in place? Expert Rev Vaccines (2013) 0.90
Bettering BCG: a tough task for a TB vaccine? Nat Med (2013) 0.89
Vaccine against tuberculosis: what's new? BMC Infect Dis (2014) 0.88
Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg (2015) 0.86
Use of antigen-specific interleukin-2 to differentiate between cattle vaccinated with Mycobacterium bovis BCG and cattle infected with M. bovis. Clin Vaccine Immunol (2013) 0.84
Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model. PLoS One (2013) 0.82
Tuberculosis vaccine types and timings. Clin Vaccine Immunol (2014) 0.81
Recent advances in the development of vaccines for tuberculosis. Ther Adv Vaccines (2015) 0.80
A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation. Hum Vaccin Immunother (2015) 0.79
High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Immunology (2014) 0.79
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One (2014) 0.79
Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice. PLoS One (2015) 0.79
Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. Vaccine (2013) 0.78
Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method. PLoS One (2014) 0.78
BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9. Cell Immunol (2013) 0.77
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines (Basel) (2014) 0.76
IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization. Int Immunol (2015) 0.76
Vaccines for TB: Lessons from the Past Translating into Future Potentials. J Immunol Res (2015) 0.76
Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother (2016) 0.75
The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75
Identification of mycobacterial RplJ/L10 and RpsA/S1 proteins as novel targets for CD4+ T cells. Infect Immun (2017) 0.75
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun (1994) 4.07
Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 3.71
Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA (2001) 3.53
Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun (2002) 3.33
Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun (2002) 3.29
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 3.04
Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis (2002) 2.90
Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol (2002) 2.83
Tuberculosis. Ann Trop Med Parasitol (2006) 2.66
Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med (2010) 2.64
Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun (2001) 2.62
Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ (2010) 2.52
T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun (1991) 2.43
Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med (2008) 2.36
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine (2005) 2.31
Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis (1998) 2.17
Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (2005) 2.08
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol (2011) 2.07
Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis (2005) 1.87
Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol (1992) 1.73
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun (2004) 1.65
Boosting vaccine for tuberculosis. Infect Immun (2001) 1.61
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One (2009) 1.45
Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol (2007) 1.42
Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology (2006) 1.41
Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog (2011) 1.40
Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One (2010) 1.37
Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun (2008) 1.26
Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.19
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine (2009) 1.09
Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population. Infect Immun (2005) 1.05
Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine (2012) 1.00
First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin (2010) 0.96
A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One (2011) 0.96
Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis (2003) 0.95
Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J Leukoc Biol (2006) 0.94
Consequence of prior exposure to environmental mycobacteria on BCG vaccination and diagnosis of tuberculosis infection. Tuberculosis (Edinb) (2008) 0.89
Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol (2010) 0.85
A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med (2011) 4.09
The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest (2011) 1.50
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One (2009) 1.45
Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol (2007) 1.42
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol (2006) 1.28
Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun (2012) 1.20
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology (2007) 1.18
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One (2009) 1.13
TB vaccines: current status and future perspectives. Immunol Cell Biol (2009) 1.12
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine (2009) 1.09
Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol (2009) 1.08
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One (2009) 1.02
Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther (2007) 1.01
The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun (2006) 0.89
Mechanism of dTTP inhibition of the bifunctional dCTP deaminase:dUTPase encoded by Mycobacterium tuberculosis. J Mol Biol (2007) 0.87
Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens. Vaccine (2011) 0.85
Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol (2010) 0.85
The CD3 gamma leucine-based receptor-sorting motif is required for efficient ligand-mediated TCR down-regulation. J Immunol (2002) 0.83
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine (2009) 0.82
Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model. PLoS One (2013) 0.82
Masking of the CD3 gamma di-leucine-based motif by zeta is required for efficient T-cell receptor expression. Traffic (2004) 0.79
A New Experimental Infection Model in Ferrets Based on Aerosolised Mycobacterium bovis. Vet Med Int (2011) 0.75